10/28/2026
BREAKING NEWS 🚨
The U.S. Department of Health and Human Services (HHS) has announced a new enforcement discretion policy that could expand access to certain compounded peptides, including BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax.
The policy allows certain compounding activities to proceed while the FDA continues its regulatory review. But it does not constitute FDA approval of these therapies.
So what does it mean for the future of peptide medicine?
Greater access creates new opportunities for patients and healthcare providers, but responsible care requires more than a prescription.
Arora CEO and Co-Founder Sean Arora, MD, emphasizes that clinical protocols, provider education, patient monitoring, and continuity of care are essential to advancing peptide therapy responsibly.
At Arora Health, we’re committed to building the physician-led infrastructure that supports evidence-informed patient care.
Swipe to read Dr. Arora’s perspective on this announcement.